drugset / Trial / NCT00853736

Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets

NCT00853736

Phase 1 Completed 23 enrolled Mallinckrodt
RandomizedCrossoverOpen-label

Summary

The objective of this open-label, randomized, two-period crossover study was to compare the oral bioavailability of a Mallinckrodt test tablet formulation of oxycodone 30 mg to an equivalent oral dose of a commercially available oxycodone tablet (Roxicodone™ 30 mg, Roxane Laboratories, Inc.) in a test group of healthy subjects under fed conditions.

Timeline

Start
2003-02
Primary completion
2003-02
Completion
2003-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxycodone Other / unclassified 30 mg Oral

Indications

No indication recorded.